CERBA Laboratory, a leading player in specialized medical biology, and BEDIA GENOMICS, an innovator in the development of diagnostic solutions, announce the implementation of the NIMO TEST at CERBA Laboratory.
The NIMO TEST, designed for non-invasive fetal Rhesus D genotyping (NIPT-RHD) from a simple maternal blood sample, is based on fully automated, fast, and highly sensitive technology. It represents a major advance in the care of pregnant women with Rhesus D-negative blood types.
“With the NIMO TEST, we are taking a new step forward in the quality and accuracy of the analyses offered to clinicians,” says Ramdane MALLEK, Head of the CERBA laboratory's genomics platform. “This collaboration with BEDIA illustrates our ongoing commitment to innovation in the service of patients.”
View the catalog here